Captor Therapeutics Reports Q3 2022 Results and Provides Business Update
Retrieved on:
Friday, November 25, 2022
TPD, Degenerative disease, Growth, Liver cancer, PLN, CTX, Monterrosa, IND, Ono Pharmaceutical, R, Partnership, Biotechnology, Therapy, Patient, IPO, Ageing, Parkinson's disease, CNS, CTA, Neurodegeneration, Cancer, WSE, Hepatocellular carcinoma, Research, Investigational New Drug, GPCR, Clinical trial, Pharmaceutical industry, Fine chemical
WROCAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for the third quarter of 2022 and provides a business update.
Key Points:
- WROCAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for the third quarter of 2022 and provides a business update.
- CT-01 is Captors lead asset and is being developed as a treatment for hepatocellular carcinoma (a form of liver cancer).
- Earlier pre-clinical studies allowed Captor to select the best drug candidate to progress to the clinic.
- The development path of Captor Therapeutics definitely fits the sought-after growth model of a biotech company.